Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Does the presence of LCIS on pathology in a patient with IDC impact your decision to offer APBI?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

It doesn’t change the decisions for APBI with all other factors being favorable. We offer APBI to invasive lobular also if it meets all criteria and had MRI breast done as part of the evaluation.

How do you approach adjuvant therapy for resected lung adenocarcinoma that was found unexpectedly postop to be N2?

6
10 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Preliminary results of the phase 3 randomized LungART trial (NCT00410683) were recently presented at a virtual ESMO conference. 501 patients with pathologically confirmed N2 NSCLC s/p complete resection were randomized to postoperative RT (54 Gy) or observation. Almost all patients received chemothe...

How would you manage a solitary, painful, lytic bony lesion in a patient with negative PET/CT but bone marrow biopsy confirmation of multiple myeloma?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

This is a palliative scenario, but the approach may differ based on the clinical circumstances. If Heme Onc is planning on administering systemic therapy, then a short course of palliative RT to expedite pain control would be appropriate. Treatment of many sites (e.g., femur) can be done very quickl...

What, if any, radiation regimen would you use for knee arthrofibrosis in a patient undergoing repeat arthroscopy with lysis of adhesions?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Radiation Medicine Associates

The high-dose single fraction regimens seem to be adapted from heterotopic ossification protocols and would be my choice if there was a concern for HO. If the concern is for the reaccumulation of fibrotic tissue, I favor LDRT such as 0.5 Gy 2-3 doses weekly for 6-8 fractions. There will be more sust...

Do you typically recommend avoiding neupogen during radiation treatments?

5
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

It depends on the reason and expected benefit. If myelosuppression is holding up RT for cervical cancer patients, then I would not hesitate to give neupogen to avoid or minimize a treatment break. There would be more benefit to neupogen and continuing RT than a downside. Usually, I would try to give...

When treating rectal cancer with TNT and induction chemotherapy first, do you repeat pelvic MRI prior to planning for chemoradiation?

6
5 Answers

Mednet Member
Mednet Member
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty

TNT approach options for pMMR T3, N any; T1–2, N1–2; T4, N any or locally unresectable or medically inoperable rectal cancer patients include:First chemotherapy for 12-16 weeks (FOLFOX or CAPEOX may also consider FOLFIRINOX) followed by long-course chemoradiation or short-course radiation, followed ...

In a patient with gastroesophageal adenocarcinoma treated with neoadjuvant chemoimmunotherapy who had a good response but is unable to undergo surgery, how would you approach radiation therapy?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Brigham and Women's Hospital

As the ARTDECO study did not show a difference in local control between 50.4 Gy and 61.6 Gy (given with carbo/taxol, but FOLFOX is also an option per PRODIGE5, depending on chemotherapy used as part of the initial chemo-IO), I would suggest 50.4 Gy.

In what cases of T3N0 glottic SCC, would you omit chemotherapy and offer radiation alone?

8
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

The question seems to stem from a presentation of a patient that would have historically been stage 2, but more recent editions of AJCC and more refined imaging have upstaged the patient to stage 3 by calling minimal paraglottic extension on an MRI. This is similar to a previous question where a pat...

When would you consider initial induction chemotherapy (e.g. FOLFOX) followed by neoadjuvant chemoradiation, over neoadjuvant chemoradiation alone, in patients with locally advanced rectal cancer?

9
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

At MSKCC, we now routinely recommend induction chemotherapy (8 cycles of FOLFOX) to any rectal cancer patient who requires preoperative chemoRT. Initially, we adopted this approach for patients with particularly bulky or node-positive disease (as per @Dr. First Last's answer above) but now do it for...

For marginal recurrences of skin cancers after prior hypofractionated radiation therapy (i.e., 30 Gy/5 fx, 55 Gy/20 fx) where there is concern for overlapping fields, could reirradiation with a hypofractionated course be considered?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · West Virginia University

For a marginal recurrence of a cutaneous malignancy after definitive hypofractionated RT, I would not necessarily offer reirradiation. I would have my plastic/dermatologic surgeon see the patient for consideration of surgical salvage, which may likely require an advanced reconstruction. If the patie...